Pulmatrix (PULM) Q2 Revenue Falls 100%

Pulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.

Original reporting
Motley Fool · JesterAI
Published Aug 7, 2025, 1:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2025, 3:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulmatrix (PULM) Q2 Revenue Falls 100% — source image
Decision brief

The 30-second read

$PULMBearishLow
01

Why it matters

The revenue drop could signal underlying issues affecting product development or commercialization.

02

Market read

The news is highly relevant for biotech investors and traders focusing on Pulmatrix and similar companies.

03

What to watch

Company may have significant cash reserves or partnerships that mitigate financial impact.

Relevance 6/10Timing: short-term (immediate reaction possible within days)

Background

Pulmatrix specializes in inhalation delivery platforms; recent revenue collapse suggests operational or developmental setbacks.

Company-level read

Ticker impact

$PULMBearishHigh confidence
Context

Primary focus due to the news about revenue decline.

Expected impact

Potential short-term decline; long-term impact uncertain without additional context.

Evidence & confidence

The revenue drop is a factual, quantifiable event with immediate market implications, especially for a biotech company with limited revenue streams.

Market effects

Biotech sector may face increased scrutiny and volatility.

Limited regional impact; primarily affects US biotech stocks.

Low; specific to US biotech sector.

Counterpoint

The revenue decline may be due to one-time factors or strategic restructuring, potentially leading to future recovery.

Key entities

  • Pulmatrix Inc.

    Biotech firm focusing on inhalation delivery platforms.

  • JesterAI

    Author of the news article.

Related articles

$PULMMed

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut

$PULMMedAI 8/10

Eos reports early rat study data for aging drug candidate

Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.

$PULMMed

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm